Despite advances in human genetics over the past decade, the fraction of the human proteome targeted by small molecules remains relatively small compared to the total number of genes linked to a disease phenotype by Mendelian inheritance or genome-wide association studies. This conference will explore how recent advances in chemical biology are helping to expand the druggable proteome and enhance our understanding of disease biology with three major themes:
illuminating the druggable genome
chemical interrogation of the druggable proteome
new engineering approaches for breaking the druggability barrier
Find Sven and Hazel in the exhibition area to find out more about how the Fluidity One-W can support your research.